Skip to main content
Premium Trial:

Request an Annual Quote

PrognosDx, MMRI Ink Epigenetics R&D Collaboration

NEW YORK (GenomeWeb News) – PrognosDx Health and the Molecular Medicine Research Institute announced recently a broad collaborative R&D agreement aimed at using PrognosDx's technology for the development of a new class of epigenetic therapeutics.

The deal provides Palo Alto, Calif.-based PrognosDx with resources to launch CLIA lab services, including a prostate cancer prognosis test and predictive tests for other cancers, the partners said.

PrognosDx now also will have a "platform for introductions to select pharma partners" for the development of new epigenetic therapeutics based on its recent "breakthrough discoveries." Initially, it and MMRI will focus on treatments for hormone refractory prostate cancer using PrognosDx's genome-wide histone modification-based biomarkers and cellular metabolism-related therapeutic insights to analyze clinical samples and carry out preclinical studies. They also plan to collaborate with academic centers on breast and gastrointestinal cancers.

As a result of the collaboration, Edward Amento, founder and executive director of MMRI, has joined PrognosDx's board.

PrognosDx uses epigenetic technology for the analysis of global histone modifications, allowing physicians to tailor cancer treatments for individual patients. Sunnyvale, Calif.-based MMRI is a non-profit institute which offers preclinical and clinical services. Its 31,000-square-foot lab has molecular biology, immunohistochemistry, flow cytometry, medicinal chemistry, cell culture, preclinical models, and other technical resources.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.